Patents Assigned to Biotechnology, Inc.
-
Patent number: 12214093Abstract: Disclosed are methods for treating platelet compositions (e.g. platelet concentrates and/or platelet lysates) with electron beam radiation, where the compositions are in a frozen state during irradiation with the e-beam radiation. The methods can be conducted using e-beam radiation at doses effective to reduce the pathogen content of the compositions while retaining highly beneficial bioactivities of the compositions. Also disclosed are compositions preparable by the methods, and methods and compositions involving the use of the e-beam treated materials.Type: GrantFiled: December 20, 2018Date of Patent: February 4, 2025Assignee: SEXTON BIOTECHNOLOGIES, INC.Inventors: Steven Charlebois, Sreedhar Thirumala
-
Patent number: 12217828Abstract: A method, apparatus, and computer-readable medium for efficiently optimizing a phenotype with a combination of a generative and a predictive model, training a phenotype prediction model based on experiential genotype vectors, training a genotype generation model based on sample genotype vectors, generating new genotype vectors, applying the phenotype prediction model to the new genotype vectors to generate scores, determining result genotypes based on a ranking of the available genotypes according to the scores, and generating a result based on the result genotypes, the result indicating one or more genetic constructs for testing.Type: GrantFiled: February 6, 2023Date of Patent: February 4, 2025Assignee: TESELAGEN BIOTECHNOLOGY INC.Inventors: Eduardo Abeliuk, Andrés Igor Pérez Manríquez, Juan Andrés Ramírez Neilson, Diego Francisco Valenzuela Iturra
-
Patent number: 12203104Abstract: The invention is directed to methods involved in the production of flavonoids, anthocyanins and other organic compounds. The invention provides cells engineered for the production of flavonoids, anthocyanins and other organic compounds, where the engineered cells include one or more genetic modifications that increase flavonoid production by increasing metabolic flux to flavonoid precursors and/or reducing carbon losses resulting from the production of byproducts.Type: GrantFiled: April 13, 2022Date of Patent: January 21, 2025Assignee: DEBUT BIOTECHNOLOGY, INC.Inventors: Jingyi Li, Nicholas Brideau, Joshua Britton, Erik Holtzapple
-
Patent number: 12195542Abstract: The invention relates to anti-Tie2 antibodies and methods of using the same.Type: GrantFiled: November 19, 2020Date of Patent: January 14, 2025Assignee: Unity Biotechnology, Inc.Inventors: Jason Damiano, Kristina Oresic Bender, Richard Theolis, Deepika Bhatnagar, Nina Ly
-
Patent number: 12195770Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.Type: GrantFiled: March 14, 2019Date of Patent: January 14, 2025Assignee: Arbor Biotechnologies, Inc.Inventors: Elise Keston-Smith, David A. Scott, David R. Cheng, Winston X. Yan, Pratyusha Hunnewell, Jason Carte
-
Publication number: 20250011423Abstract: Soluble TREML1 is involved in many inflammatory diseases and plays an important role in immune suppression. Soluble TREML1 can bind the l-domain of CD11b and induce an immune suppressive phenotype. Thus, soluble TREML1 may be a good target for treating inflammatory diseases. The present invention relates to antibodies that can reduce soluble TREML1 binding to CD11b+ immune cells and their uses for reversing TREML14 induced immune suppression. Anti-TREML1 antibodies provide a novel and potential therapy for these disease conditions such as cancer.Type: ApplicationFiled: November 15, 2022Publication date: January 9, 2025Applicant: Ascendo Biotechnology, Inc.Inventors: Yen-Ta Lu, Chia-Ming Chang, Yi-Chen Chen, I-Fang Tsai
-
Publication number: 20250002473Abstract: The present disclosure relates to at least one entity chosen from a compound of Formula (I), tautomers, stereoisomers or a mixture of stereoisomers, hydrates, and deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, and their use as epidermal growth factor receptor (EGFR) degraders for the prevention and treatment of diseases and conditions, e.g., cancer. The present disclosure also relates to pharmaceutical compositions containing such entities, and their use in treating or preventing a disease or disorder associated with EGFR.Type: ApplicationFiled: June 14, 2024Publication date: January 2, 2025Applicant: Accutar Biotechnology Inc.Inventors: Ji LIU, Pin HUANG, Ke LIU, Wei HE, Yimin QIAN, Jie FAN, Robert Luo
-
Patent number: 12180495Abstract: Polynucleotides incorporated into nucleic acid constructs have been introduced into plants and were ectopically expressed. The encoded polypeptides of the invention have been shown to confer at least one regulatory activity and confer earlier flowering, longer floral organ retention, increased cold tolerance, greater tolerance to water deprivation, altered carbon-nitrogen balance sensing, increased low nitrogen tolerance, and/or increased tolerance to hyperosmotic stress as compared to a control plant.Type: GrantFiled: September 6, 2023Date of Patent: December 31, 2024Assignees: Mendel Biotechnology, Inc., Monsanto Technology LLCInventors: Jose Luis Riechmann, Oliver J. Ratcliffe, T. Lynne Reuber, Katherine Krolikowski, Jacqueline E. Heard, Omaira Pineda, Cai-Zhong Jiang, Robert A. Creelman, Roderick W. Kumimoto, Paul S. Chomet
-
Patent number: 12180491Abstract: An isolated expression enhancer active in a plant, portion of a plant or plant cell, the expression enhancer is provided. The isolated expression enhancer may be selected from the group consisting of nbMT78 (SEQ ID NO:1); nbATL75 (SEQ ID NO:2); nbDJ46 (SEQ ID NO:3); nbCHP79 (SEQ ID NO:4); nbEN42 (SEQ ID NO:5); atHSP69 (SEQ ID NO:6); atGRP62 (SEQ ID NO:7); atPK65 (SEQ ID NO:8); atRP46 (SEQ ID NO:9); nb30S72 (SEQ ID NO:10); nbGT61 (SEQ ID NO:11); nbPV55 (SEQ ID NO:12); nbPPI43 (SEQ ID NO:13); nbPM64 (SEQ ID NO:14); and nbH2A86 (SEQ ID NO:15). Methods for using the isolated expression enhancer are also provided.Type: GrantFiled: March 14, 2019Date of Patent: December 31, 2024Assignee: ARAMIS BIOTECHNOLOGIES INC.Inventors: Pierre-Oliver Lavoie, Marc-Andre D'Aoust, Ko Kato, Shotaro Yamasaki
-
Publication number: 20240425820Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells. In some embodiments, the engineered cells comprise increased expression of CD46 and CD59.Type: ApplicationFiled: August 11, 2022Publication date: December 26, 2024Applicant: Sana Biotechnology, Inc.Inventor: Sonja SCHREPFER
-
Publication number: 20240424050Abstract: The present disclosure generally relates to compositions comprising dihexa and methods for making or using said compositions. In some aspects, the compositions disclosed herein may comprise one or more additional active ingredients, including lipoic acid, spadin peptide, and/or phenyl-N-tert-butylnitrone. Compositions such as these may be used in certain embodiments, for example, to enhances a subject's hearing or to treat a hearing disorder, etc. In some embodiments, the compositions are topical compositions configured to treat hearing loss via administration, e.g., to the skin behind the outer ear or directly to the eardrum of a subject, etc. In some cases, the compositions disclosed herein may comprise one or more excipients to aid in transdermal delivery. For instance, in certain embodiments, the compositions comprise lecithin and/or other components that may facilitate delivery through the skin.Type: ApplicationFiled: April 4, 2024Publication date: December 26, 2024Applicant: Transdermal Biotechnology, Inc.Inventor: Nicholas V. Perricone
-
Publication number: 20240425519Abstract: Spirocyclic compounds that are KLHDC2 ligands and methods for inhibiting the enzymatic activity of KLHDC2 using the ligands.Type: ApplicationFiled: October 31, 2022Publication date: December 26, 2024Applicants: University of Washington, ACCUTAR BIOTECHNOLOGY INC.Inventors: Ning ZHENG, Domnita Valeria RUSNAC, Jie FAN, Yimin QIAN, Ke LIU
-
Patent number: 12173077Abstract: The present invention is directed to a humanized BCMA antibody or an antigen-binding fragment thereof, comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity against BCMA-positive tumor cells.Type: GrantFiled: May 31, 2023Date of Patent: December 24, 2024Assignees: ProMab Biotechnologies, Inc., Forevertek Biotechnology Co., LtdInventors: Lijun Wu, Vita Golubovskaya
-
Patent number: 12168008Abstract: The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.Type: GrantFiled: December 8, 2017Date of Patent: December 17, 2024Assignees: Lixte Biotechnology, Inc., The United States of America, as Represented by the Secretary Department of Health and Human ServicesInventors: John S. Kovach, Zhengping Zhuang, Sze Chun Winson Ho, Herui Wang, Rongze Lu
-
Publication number: 20240408171Abstract: An aqueous formulation includes a PEDF-derived short peptide (PDSP) having the sequence of one of SEQ ID NO: 1, 2, 3, 5, 6, 8 or 9; boric acid at a concentration of 0.01 mM-923 mM; and a non-ionic tonicity agent. The pH value is around 5.5-8.4. The non-ionic tonicity agent is glycerin, sucrose, mannitol, or sorbitol. A concentration of the PDSP is 0.01%-1% w/v.Type: ApplicationFiled: January 24, 2022Publication date: December 12, 2024Applicant: BRIM Biotechnology, Inc.Inventors: Frank Wen-Chi Lee, Wayne Wei-Cheng Liaw, Jason Ping-Yen Huang, Emily Hsiao-Han Wang
-
Publication number: 20240408192Abstract: Provided herein are lipid particles, such as lenti viral particles, that incorporate or are pseudotyped with a variant Nipah Virus G (NiV-G) envelope glycoprotein, and in some aspects also a fusion (F) protein such as a NiV-F protein or a biologically active portion or variant thereof. Also provided are polynucleotides encoding the variant NiV-G and producer cells for preparation of the lipid particles, such as lentiviral particles, containing the variant NiV-G proteins, as well as methods for preparing and using the lipid particles, such as lentiviral particles.Type: ApplicationFiled: December 16, 2022Publication date: December 12, 2024Applicant: Sana Biotechnology, Inc.Inventors: Christopher BANDORO, Lauren Pepper MACKENZIE, Jagesh Vijaykumar SHAH, Kyle Marvin TRUDEAU
-
Publication number: 20240409908Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of DNA, RNA, and protein substrates. Each system includes one or more protein components and one or more nucleic acid components that together target DNA, RNA, or protein substrates.Type: ApplicationFiled: June 13, 2024Publication date: December 12, 2024Applicant: Arbor Biotechnologies, Inc.Inventors: David A. Scott, David R. Cheng, Winston X. Yan
-
Patent number: 12161748Abstract: A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation.Type: GrantFiled: March 26, 2021Date of Patent: December 10, 2024Assignee: TWI BIOTECHNOLOGY, INC.Inventors: Chih-Ming Chen, Guang-Wei Lu, Ling-Ying Liaw, Fan-Lun Liu, Shih-Fen Liao, Chou-Hsiung Chen, Yu-Han Kao, Yu-Yin Chen
-
Publication number: 20240398805Abstract: The disclosure provides quinazoline based compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.Type: ApplicationFiled: February 4, 2022Publication date: December 5, 2024Applicant: ACCUTAR BIOTECHNOLOGY INC.Inventors: Yimin Qian, Wei HE, Robert LUO, Jie Fan
-
Publication number: 20240401064Abstract: A bacteria-mediated platform that uses invasive, non-pathogenic bacteria to both produce and intracellularly deliver antibodies, antibody derivatives, and proteins/polypeptides to targeted eukaryotic cells and tissues. The bacteria can contain a prokaryotic expression cassette encoding the protein cargo.Type: ApplicationFiled: June 2, 2022Publication date: December 5, 2024Applicant: SiVEC Biotechnologies, Inc.Inventors: Lyndsey M Linke, Ashley B Williams, Darcy Mora, Madeline Cox, Timothy Enroth